Overview

Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium (PROMIS II)

Status:
Recruiting

Trial end date:
2021-11-30

Target enrollment:

Participant gender:

Summary

The primary objective of the trial is to investigate the effect of the use of inhaled colistimethate sodium, administered twice daily via the I-neb for 12 months, compared to placebo in subjects with non-cystic fibrosis bronchiectasis (NCFB) chronically infected with P. aeruginosa on the frequency of pulmonary exacerbations.

Phase:

Phase 3

Details

Lead Sponsor:

Zambon SpA

Treatments:

Colistin
Pharmaceutical Solutions